Clinical Research Directory

Inclusion Criteria: 1. Age ≥ 18 years. 2. Diagnosis of acute ischemic stroke, with no evidence of hemorrhagic transformation confirmed by acute neuroimaging (MRI and CT). 3. Documented history of spontaneous intracerebral hemorrhage (ICH). 4. Confirmed non-valvular atrial fibrillation (including paroxysmal, persistent, or permanent subtypes). 5. Provision of written informed consent by the patient or a legally authorized representative. Exclusion Criteria: 1. Severe baseline disability, defined as a pre-stroke Modified Rankin Scale (mRS) score \> 4. 2. Intracerebral hemorrhage definitively caused by underlying structural vascular lesions (e.g., AVM, aneurysm) or systemic diseases. 3. Severe, uncontrolled hypertension refractory to medical therapy. 4. Severe renal impairment, defined as an estimated Creatinine Clearance (CrCl) \< 30 mL/min. 5. Clinical indications necessitating continuous oral anticoagulation therapy other than atrial fibrillation (e.g., mechanical prosthetic heart valves, deep vein thrombosis, pulmonary embolism). 6. Documented contraindications to direct oral anticoagulants according to the product summary of characteristics (excluding the previous spontaneous ICH), including but not limited to hypersensitivity, active clinically significant bleeding, high-risk bleeding lesions, or hepatic disease associated with coagulopathy and clinically relevant bleeding risk. 7. Prior deployment of, or planned procedure for, a left atrial appendage occlusion (LAAO) device. 8. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial period. 9. Estimated life expectancy of less than 1 year due to concomitant terminal illness.